Castle Biosciences Stock News

Castle Biosciences announced it has completed its acquisition of Cernostics, Inc.

Castle Biosciences Inc. (NASDAQ:CSTL) concluded the trading at $41.43 on Friday, December 03 with a fall of -1.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $41.92 with its price kept floating in the range of $40.225 and $42.58 on the Castle Biosciences Inc. (CSTL) Is A Stock Worth Accumulating At Current Levels Read More »

Castle Biosciences, Inc. (NASDAQ:CSTL) reached a new 52-week low during trading on Monday . The company traded as low as $41.14 and last traded at $41.48, with a volume of 8168 shares trading hands. The stock had previously closed at $43.12. A number of research analysts have commented on the stock. SVB Leerink reduced their []

Prudential Financial Inc. acquired a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,901 shares of the companys stock, valued at approximately $286,000. A number of other large investors have also recently bought and []

Castle Biosciences Inc (CSTL) shares closed 2.7% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 35.8% year-to-date, down 3.0% over the past 12 months, and up 101.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 0.6%. Trading Activity Trading volume this week was 53.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 185.9% The company's stock price performance over the past 12 months beats the peer average by -35.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Brokerages expect Castle Biosciences, Inc. (NASDAQ:CSTL) to report sales of $23.43 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Castle Biosciences earnings. The highest sales estimate is $23.45 million and the lowest is $23.40 million. Castle Biosciences reported sales of $17.30 million in the same quarter last year, which [] The post Zacks: Analysts Anticipate Castle Biosciences, Inc. (NASDAQ:CSTL) Will Announce Quarterly Sales of $23.43 Million appeared first on ETF Daily News .

Castle Biosciences Inc (CSTL) shares closed today at 0.8% above its 52 week low of $42.78, giving the company a market cap of $1B. The stock is currently down 33.2% year-to-date, up 2.9% over the past 12 months, and up 109.6% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 43.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.1. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 203.2% The company's stock price performance over the past 12 months beats the peer average by -237.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

During the last session, Castle Biosciences Inc. (NASDAQ:CSTL)s traded shares were 0.35 million. At the end of the trading day, the stocks price was $44.86, reflecting an intraday gain of 0.81% or $0.36. The 52-week high for the CSTL share is $107.69, that puts it down -140.06 from that peak though still a striking 4.64% After A -14.39% Drop In The Last Week, Does Castle Biosciences Inc. (NASDAQ: CSTL) Still Make Sense To Buy? Read More »

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle announced oral presentations on its DecisionDx® skin cancer tests at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting.

Level Four Advisory Services LLC purchased a new stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) in the 3rd quarter, Holdings Channel.com reports. The fund purchased 5,265 shares of the companys stock, valued at approximately $350,000. Several other hedge funds have also added to or reduced their stakes in CSTL. Dimensional Fund Advisors LP raised []

Castle Biosciences, Inc. (NASDAQ:CSTL) saw a large decrease in short interest in October. As of October 29th, there was short interest totalling 846,200 shares, a decrease of 14.8% from the October 14th total of 992,900 shares. Based on an average daily volume of 168,500 shares, the short-interest ratio is currently 5.0 days. Approximately 4.8% of []

Equities analysts expect that Castle Biosciences, Inc. (NASDAQ:CSTL) will post sales of $23.43 million for the current quarter, according to Zacks. Two analysts have issued estimates for Castle Biosciences earnings. The highest sales estimate is $23.45 million and the lowest is $23.40 million. Castle Biosciences posted sales of $17.30 million in the same quarter last []

Wall Street brokerages expect Castle Biosciences, Inc. (NASDAQ:CSTL) to post earnings per share (EPS) of ($0.43) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Castle Biosciences earnings. The lowest EPS estimate is ($0.47) and the highest is ($0.39). Castle Biosciences reported earnings per share of ($0.16) in []

The stock price of Castle Biosciences (NASDAQ: CSTL), a skin cancer diagnostic company, has seen a fall of over 9% last month, while it is down 12% in a week. The recent fall can be attributed to its

Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q3 2021 Results - Earnings Call Transcript